Amylyx Raises $500 Million to Advance Avexitide After Positive Phase 3 PBH Results

Amylyx Pharmaceuticals priced an upsized underwritten public offering expected to generate $500.2 million in gross proceeds, the company announced August 19, 2026, a day after reporting positive phase 3 (LUCIDITY) results for avexitide in post-bariatric hypoglycemia (PBH).¹ Amylyx said it will use the proceeds to fund pre-commercial activities for avexitide, including securing additional manufacturing capacity, along with research and development and working capital.¹

What did the phase 3 LUCIDITY trial show?

The phase 3 LUCIDITY trial (NCT06747468) enrolled 78 adults with PBH following Roux-en-Y gastric bypass surgery, randomized 3:2 to receive 90 mg avexitide subcutaneously once daily or placebo.² The trial met its FDA-agreed-upon primary endpoint, showing a 55% reduction in the composite rate of level 2 and level 3 hypoglycemic events compared with placebo through week 16 (p=0.000003).²

LUCIDITY also met all secondary endpoints, with consistent, statistically significant reductions across level 2 events measured by self-monitoring of blood glucose, level 2 events measured by continuous glucose monitoring, and independently adjudicated level 3 events.² Avexitide was generally well tolerated, with mostly mild to moderate adverse events and no serious adverse events related to treatment. The most common adverse events reported were diarrhea, injection site erythema, and injection site bruising.²

Why does this matter for patients with PBH?

PBH is a chronic metabolic condition estimated to affect about 8% of people in the United States who have undergone sleeve gastrectomy or Roux-en-Y gastric bypass surgery, or approximately 160,000 people.² The condition is driven by an exaggerated GLP-1 response that leads to excessive insulin secretion and recurrent, often severe drops in blood glucose. Level 2 and level 3 hypoglycemic events can cause confusion, loss of consciousness, and seizures, and there are currently no FDA-approved therapies for PBH.²

Avexitide is a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist designed to block the exaggerated GLP-1 response at the pancreatic islet beta cell level, an approach earlier validated in the phase 2 PREVENT trial, in which avexitide significantly reduced hypoglycemic events and raised glucose nadir compared with placebo in patients with severe PBH.³

What's next for avexitide?

Amylyx plans to submit a new drug application to the FDA by the end of 2026 and said it is preparing for a potential commercial launch of avexitide in 2027 if approved.² Avexitide holds FDA breakthrough therapy and orphan drug designations. The LUCIDITY open-label extension and the company's avexitide expanded access program both remain ongoing.²

What are the limitations?

These are topline results, and full data have not yet been presented at a medical meeting or published in a peer-reviewed journal. The offering is expected to close on or about August 21, 2026, subject to customary closing conditions.

References

1. Amylyx Pharmaceuticals. Amylyx Pharmaceuticals announces pricing of an upsized $500 million underwritten public offering of common stock. Press release. Published August 19, 2026. Accessed August 20, 2026. https://www.amylyx.com/news/amylyx-pharmaceuticals-announces-pricing-of-an-upsized-500-million-underwritten-public-offering-of-common-stock
2. Amylyx Pharmaceuticals. Amylyx Pharmaceuticals announces positive topline results from Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia. Press release. Published August 18, 2026. Accessed August 20, 2026. https://www.amylyx.com/news/amylyx-pharmaceuticals-announces-positive-topline-results-from-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia
3. Craig CM, Lawler HM, Lee CJE, et al. PREVENT: a randomized, placebo-controlled crossover trial of avexitide for treatment of postbariatric hypoglycemia. J Clin Endocrinol Metab. 2021;106(8):e3235-e3248. doi:10.1210/clinem/dgab103